Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 6/20 | 0.39 |
| ▸ | CDK8 | P49336 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTAFR | P25105 | 3/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81597 | 0.89 | PIK3CB (0.38) | PIK3CBPIK3CGCCNCCDK8ALDH1A1 | |
| SCHEMBL86622 | 0.89 | CCNC (0.39) | PIK3CBPIK3CGCCNCCDK8ALDH1A1 | |
| SCHEMBL86616 | 0.87 | TDP1 (0.43) | CCNCCDK8PTAFRNPC1TSHR | |
| SCHEMBL86871 | 0.86 | PIK3CB (0.46) | PIK3CBPIK3CGALDH1A1PTAFRDNMT1 | |
| Hydrochloric Acid SCHEMBL80801 | 0.84 | HDAC1 (0.44) | ALDH1A1PTAFRMEN1KMT2ANPC1 | |
| SCHEMBL86838 | 0.83 | NAMPT (0.39) | PIK3CBPIK3CGCCNCCDK8ALDH1A1 | |
| SCHEMBL12533965 | 0.81 | ALDH1A1 (0.39) | ALDH1A1PTAFRMEN1KMT2ANPC1 | |
| SCHEMBL86990 | 0.81 | NPC1 (0.39) | PIK3CBPIK3CGALDH1A1PTAFRDNMT1 | |
| SCHEMBL86842 | 0.81 | MEN1 (0.39) | PIK3CBPIK3CGPTAFRDNMT1RAD52 | |
| SCHEMBL86640 | 0.81 | CCNC (0.41) | PIK3CBPIK3CGCCNCCDK8PTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| EP-2042504-B1 | Fused azole-pyrimidine derivatives | BAYER SCHERING PHARMA AG (DE) | 2011-06-01 | — | — | EP | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | PIK3CB 5/4885PIK3CG 4/4885CCNC 728/4885 |
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | KIT, CSNK2A1, CSNK1A1 | PIK3CB 570/4885PIK3CG 866/4885CCNC 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.